Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + corticosteroids (Peking Union Medical College Hospital)
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of **ruxolitinib**, a small molecule Janus kinase (JAK) 1 and 2 inhibitor, and standard-of-care **corticosteroids** (such as prednisone or methylprednisolone). It is being investigated by **Peking Union Medical College Hospital** for the management of severe (Grade 3-4) **checkpoint inhibitor pneumonitis (CIP)**, a potentially fatal immune-related adverse event (irAE) occurring in cancer patients treated with immune checkpoint inhibitors. Ruxolitinib specifically targets the JAK-STAT signaling pathway to block the downstream effects of inflammatory cytokines, while corticosteroids provide broad, non-specific immunosuppression. The clinical trial aims to determine if the addition of ruxolitinib to standard steroid therapy can improve clinical outcomes, reduce the total corticosteroid dose required, and provide a therapeutic option for patients who are refractory to steroids alone.
- Other names
- ruxolitinib and corticosteroidsruxolitinib + prednisoneruxolitinib + methylprednisolone
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)GR (Glucocorticoid receptor)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on ruxolitinib + corticosteroids (Peking Union Medical College Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + corticosteroids (Peking Union Medical College Hospital).